Smithfield Trust’s Neurocrine Biosciences NBIX Stock Holding History

Smithfield Trust’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50K	Buy	+295	New	+$43.8K	﹤0.01%	612
2026 Q1	–	Sell	-71	Closed	-$10K	–	1099
2025 Q4	$10K	Buy	+71	New	+$10.3K	﹤0.01%	883
2025 Q1	–	Sell	-60	Closed	-$8K	–	1066
2024 Q4	$8K	Hold	60	–	–	﹤0.01%	907
2024 Q3	$6K	Hold	60	–	–	﹤0.01%	926
2024 Q2	$8K	Hold	60	–	–	﹤0.01%	859
2024 Q1	$8K	Hold	60	–	–	﹤0.01%	875
2023 Q4	$8K	Hold	60	–	–	﹤0.01%	862
2023 Q3	$6K	Hold	60	–	–	﹤0.01%	888
2023 Q2	$6K	Hold	60	–	–	﹤0.01%	900
2023 Q1	$6K	Hold	60	–	–	﹤0.01%	870
2022 Q4	$7K	Hold	60	–	–	﹤0.01%	842
2022 Q3	$6K	Hold	60	–	–	﹤0.01%	876
2022 Q2	$6K	Hold	60	–	–	﹤0.01%	931
2022 Q1	$6K	Hold	60	–	–	﹤0.01%	954
2021 Q4	$6K	Hold	60	–	–	﹤0.01%	963
2021 Q3	$6K	Hold	60	–	–	﹤0.01%	972
2021 Q2	$6K	Sell	60 -10	-14%	-$958	﹤0.01%	955
2021 Q1	$7K	Hold	70	–	–	﹤0.01%	940
2020 Q4	$7K	Hold	70	–	–	﹤0.01%	908
2020 Q3	$7K	Sell	70 -14	-17%	-$1.62K	﹤0.01%	850
2020 Q2	$10K	Buy	84 +14	+20%	+$1.55K	﹤0.01%	742
2020 Q1	$6K	Hold	70	–	–	﹤0.01%	753
2019 Q4	$8K	Hold	70	–	–	﹤0.01%	729
2019 Q3	$6K	Hold	70	–	–	﹤0.01%	806
2019 Q2	$6K	Hold	70	–	–	﹤0.01%	786
2019 Q1	$6K	Hold	70	–	–	﹤0.01%	742
2018 Q4	$5K	Hold	70	–	–	﹤0.01%	751
2018 Q3	$9K	Hold	70	–	–	﹤0.01%	743
2018 Q2	$7K	Buy	+70	New	+$6.27K	﹤0.01%	779

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Smithfield Trust's NBIX Position: Q2 2026 in Review

Smithfield Trust opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 295 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #612 among its holdings. This is a return to the name: Smithfield Trust previously reported a position in NBIX as recently as Q4 2025.

Smithfield Trust first reported a position in NBIX in Q2 2018 and has held it in 29 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Smithfield Trust held 295 shares of Neurocrine Biosciences worth $50K as of Q2 2026.
Neurocrine Biosciences was a new Smithfield Trust position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Smithfield Trust's portfolio in Q2 2026, its #612 holding.
Smithfield Trust first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 29 quarters since.
778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Smithfield Trust's 13F filing for Q2 2026, filed 5 Aug 2026.